Nicholas Wrigley

Articles

Polatuzumab Vedotin Substitution in R-mini-CHOP Does Not Worsen High-Grade Toxicities in DLBCL

June 13th 2023

Using polatuzumab vedotin instead of vincristine in a reduced-dose regimen of rituximab, cyclophosphamide, doxorubicin, and prednisone was not found to increase grade 3/4 hematologic toxicities, infection risk, or neuropathy in elderly patients with untreated diffuse large B-cell lymphoma.

TAS-102 Plus Bevacizumab Fails to Extend OS in Unresectable mCRC

June 5th 2023

The combination of trifluridine/tipiracil and bevacizumab did not demonstrate a significant overall survival benefit vs capecitabine plus bevacizumab in patients with unresectable, metastatic colorectal cancer ineligible for intensive chemotherapy.

Dostarlimab Plus Chemo Leads to PFS Improvement in dMMR/MSI-H Advanced Endometrial Cancer

June 4th 2023

The combination of dostarlimab with standard-of-care carboplatin and paclitaxel elicited a statistically significant and clinically meaningful improvement in progression-free survival vs carboplatin/paclitaxel plus placebo in patients with mismatch repair–deficient/microsatellite instability–high advanced or recurrent endometrial cancer.

Cabozantinib Plus Nivolumab/Ipilimumab Shows Notable PFS Improvement in Intermediate-Risk, Advanced RCC

February 18th 2023

The combination of frontline cabozantinib, nivolumab, and ipilimumab led to a greater improvement in progression-free survival in patients with intermediate- vs poor-risk advanced renal cell carcinoma.

Niraparib Plus Abiraterone/Prednisone Maintains rPFS Benefit in HRR Gene–Altered mCRPC

February 17th 2023

The combination of niraparib, abiraterone acetate, and prednisone produced prolonged survival and delayed progression rates in patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.

Patient-specific Marker Tracking Approach May Better Detect MRD in CRC

January 22nd 2023

A novel Burning Rock patient-specific prognostic and potential therapeutic marker tracking approach demonstrated improved sensitivity in detecting circulating tumor DNA and identifying molecular residual disease compared with other approaches in patients with colorectal cancer following surgery.

Rapcabtagene Autoleucel Induces Deep, Durable Responses in Relapsed/Refractory DLBCL

December 11th 2022

The CD19-targeted CAR T-cell therapy rapcabtagene autoleucel was found to be well tolerated and to yield durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma who had undergone 2 or more prior lines of therapy.